Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach

References

• CarrollPRParsonsJKAndrioleGNCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015J Natl Compr Canc Netw201513121534156126656522
   PubMed Web of Science ®Google Scholar
• PagliaruloVBracardaSEisenbergerMAContemporary role of androgen deprivation therapy for prostate cancerEur Urol2012611112521871711
   PubMed Web of Science ®Google Scholar
• KumarRJBarqawiACrawfordEDAdverse events associated with hormonal therapy for prostate cancerRev Urol20057Suppl 5S37S4316985883
   PubMedGoogle Scholar
• GiacaloneAQuitadamoDZanetEBerrettaMSpinaMTirelliUCancer-related fatigue in the elderlySupport Care Cancer201321102899291123852408
   PubMed Web of Science ®Google Scholar
• BourkeLKirkbridePHooperRRosarioAJChicoTJRosarioDJEndocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?Br J Cancer2013108191323321508
   PubMed Web of Science ®Google Scholar
• ShahinianVBKuoYFFreemanJLGoodwinJSRisk of the “androgen deprivation syndrome” in men receiving androgen deprivation for prostate cancerArch Intern Med2006166446547116505268
   PubMedGoogle Scholar
• GrossmannMZajacJDHematological changes during androgen deprivation therapyAsian J Androl201214218719222231300
   PubMed Web of Science ®Google Scholar
• JespersenCGNorgaardMBorreMAndrogen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort studyEur Urol201465470470923433805
   PubMed Web of Science ®Google Scholar
• LangleyRECaffertyFHAlhassoAACardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)Lancet Oncol201314430631623465742
   PubMed Web of Science ®Google Scholar
• KrahnMDBremnerKELuoJAlibhaiSMHealth care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse eventsCurr Oncol2014213e457e46524940106
   PubMed Web of Science ®Google Scholar
• TunnUWCanepaGKochanowskyAKienleETestosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapyProstate Cancer Prostatic Dis201215329630222733160
   PubMed Web of Science ®Google Scholar
• RosarioDJBourkeLReply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?Br J Cancer201310810219423632481
   PubMed Web of Science ®Google Scholar
• BruchovskyNRenniePSColdmanAJGoldenbergSLToMLawsonDEffects of androgen withdrawal on the stem cell composition of the Shionogi carcinomaCancer Res1990508227522822317815
   PubMed Web of Science ®Google Scholar
• BarentszJORichenbergJClementsRESUR prostate MR guidelines 2012Eur Radiol201222474675722322308
   PubMed Web of Science ®Google Scholar
• HorwichAHugossonJde ReijkeTProstate cancer: ESMO Consensus Conference Guidelines 2012Ann Oncol20132451141116223303340
   PubMed Web of Science ®Google Scholar
• HigginsJGreenSECochrane Handbook for Systematic Reviews of InterventionsThe Cochrane Collaboration2011 Available from: www.cochrane-handbook.orgAccessed October 1, 2017
   Google Scholar
• SheaBJGrimshawJMWellsGADevelopment of AMSTAR: a measurement tool to assess the methodological quality of systematic reviewsBMC Med Res Methodol200771017302989
   PubMed Web of Science ®Google Scholar
• GuyattGOxmanADAklEAGRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tablesJ Clin Epidemiol201164438339421195583
   PubMed Web of Science ®Google Scholar
• Martinez GarciaLSanabriaAJArayaIEfficiency of pragmatic search strategies to update clinical guidelines recommendationsBMC Med Res Methodol2015155726227021
   PubMed Web of Science ®Google Scholar
• Martinez GarciaLSanabriaAJGarcia AlvarezEThe validity of recommendations from clinical guidelines: a survival analysisCMAJ2014186161211121925200758
   PubMed Web of Science ®Google Scholar
• MagnanSZarychanskiRPiloteLIntermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysisJAMA Oncol2015191261126926378418
   PubMed Web of Science ®Google Scholar
• SchulmanCCornelEMatveevVIntermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: a phase 3b randomised study (Iceland)Eur Urol201669472072726520703
   PubMed Web of Science ®Google Scholar
• CrawfordDShoreNHiganoCSNeijberAYankovVIntermittent androgen deprivation with the gonadotrophin releasing hormone antagonist degarelixJ Urol20141914 Suppl 1e766
   Web of Science ®Google Scholar
• CasasFHenriquezIBejarAIntermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR studyClin Transl Oncol201719337337827770397
   PubMed Web of Science ®Google Scholar
• Chun-Leung ChauDWangDTedescoAProstate cancer patients’ preferences for intermittent vs. continuous androgen deprivation— a pilot institutional studyJ Med Imaging Radiat Sci2016471108112 e102
   PubMedGoogle Scholar
• CrawfordDShoreNHiganoCSNeijberAYankovVIntermittent androgen deprivation with the GnRH antagonist degarelix in men with biochemical relapse of prostate cancerAm J Hematol Oncol20151112613
   Google Scholar
• BultijnckRSurcelCPloussardGPractice patterns compared with evidence-based strategies for the management of androgen deprivation therapy–induced side effects in prostate cancer patients: results of a European web-based surveyEur Urol Focus20162551452128723517
   PubMedGoogle Scholar
• LiedeAHallettDCHopeKGrahamAArellanoJShahinianVBInternational survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countriesESMO Open201612e00004027843596
   PubMedGoogle Scholar
• HurwitzLMCullenJElsamanoudiSA prospective cohort study of treatment decision-making for prostate cancer following participation in a multidisciplinary clinicUrol Oncol2016345233.e1725
   PubMed Web of Science ®Google Scholar